



**A**Basal




















**Supplementary Figure 2.** Expression of Golgi-GRK2ct and Golgi-GRK2cR587Q at the Golgi. Golgi-GRK2ct and its mutant were transiently expressed in cells and their localization was revealed by confocal microscopy following staining with GRK2 antibodies. Similar results were obtained in 2 experiments. Scale bar: 10  $\mu$ m.




**Supplementary Figure 3.** CRISPR-Cas9-mediated  $G\gamma9$  knockout abolishes ERK1/2 activation. (A) Expression of YFP-tagged  $G\gamma2$ ,  $G\gamma3$  and  $G\gamma9$  in CRISPR-Cas9-mediated  $G\gamma3$  and  $G\gamma9$  knockout cells. The cells were cultured on 6-well dishes and transfected with 1.5 μg of individual YFP- $G\gamma$  for 48 h and YFP- $G\gamma$  expression was measured by Western blotting using YFP antibodies. (B) Time courses of ERK1/2 activation by SDF1 $\alpha$  at 200 ng/ml in control and  $G\gamma9$  knockout PC3 cells. (C) Quantitative data shown in (B). (D) Expression of sgRNA-resistant  $G\gamma9$ . Control or  $G\gamma9$  knockout PC3 cells were transiently transfected with or without YFP, YFP-tagged  $G\gamma9$ , YFP-tagged sgRNA-resistant  $G\gamma9$  ( $G\gamma9$ res). Expression of YFP, endogenous  $G\gamma9$  and YFP- $G\gamma9$  was detected by immunoblotting using  $G\gamma9$  (top panel) and YFP antibodies (middle panel). Expression of  $\beta$ -actin was used a loading control (bottom panel). In each panel, similar results were obtained in at least 3 experiments.




**Supplementary Figure 4.** Inducible translocation of  $G\beta\gamma$  to the GA and the PM in DU145, PC3 and HEK293 cells. The cells were transiently transfected with venus- $G\beta1$  and FRB- $G\gamma9$ , together with either Golgi-FKBP for Golgi targeting (Golgi- $G\gamma9$ , left panel) or PM-KFBP for PM targeting (PM- $G\gamma9$ , right panel) (500 ng each), and then induced with rapamycin at 1  $\mu$ M for 30 min.  $G\beta\gamma$  translocation was revealed by confocal microscopy detecting venus- $G\beta1$ . Similar results were obtained in 2 separate experiments. Scale bar: 10  $\mu$ m.




Supplementary Figure 5. Golgi fragmentation induced by Golgi disruptors. The cells were transiently transfected with YFP-GalT and then treated with BFA (3  $\mu$ M), ilimaquinone (10  $\mu$ M), monensin (5  $\mu$ M), nigericin (2  $\mu$ M), nocodazole (10  $\mu$ M) and swainsonine (5  $\mu$ M) for 40 min. The Golgi fragmentation was revealed by confocal microscopy. Similar results were obtained in 3 separate experiments. Scale bar: 10  $\mu$ m.



**Supplementary Figure 6** Colocalization of p110 $\gamma$  and p101 subunits of PI3K $\gamma$  with the Golgi marker. (A) PC3 cells were transfected with DsRed-tagged p110 $\gamma$ , GFP-tagged p101 and the Golgi marker pmTurquoise2-Golgi. (B) PC3 cells were transfected with DsRed-tagged p101, GFP-tagged p110 $\gamma$  and pmTurquoise2-Golgi. Their subcellular localization was revealed by confocal microscopy. Similar results were obtained in 3 separate experiments. Scale bars: 10  $\mu$ m.



Supplementary Figure 7. Role of G $\beta\gamma$  and PI3K in ERK1/2 activation by  $\alpha_2$ -AR. (A) Role of G $\beta\gamma$  in ERK1/2 activation by  $\alpha_2$ -AR. The cells were treated with PTX (100 ng/ml for 16 h), gallein (10  $\mu$ M for 30 min) or rauwolscine (100  $\mu$ M for 1 h) before UK14304 stimulation at 1  $\mu$ M for 5 min. (B) The cells were treatment with LY294002 (50  $\mu$ M), wortmannin (10  $\mu$ M), HS-173 (0.1  $\mu$ M), TGX-221 (0.5  $\mu$ M), AS-604850 (2.5  $\mu$ M), GSK2292767 (0.5  $\mu$ M) for 6 h before UK14304 stimulation. The Western blots shown in each panel are representatives of 3 experiments.



**Supplementary Figure 8.** Quantitative data of Western blots shown in the manuscript. \*, P < 0.05 vs respective ctrl in Fig. 2, 3D, 4 and 5, vs SDF1 $\alpha$  in Fig. 3A, and vs  $\beta$ 1 $\gamma$ 9 in Fig. 3G.